Navigation Links
BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
Date:10/15/2009

PHILADELPHIA, Oct. 15 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced receipt of two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The funding is intended to support further commercial development of BioNanomatrix's nanoscale whole genome imaging and analysis platform. BioNanomatrix plans to use the funds to prepare for the upcoming beta site launch of its first commercial NanoAnalyzer® system, planned for the second quarter of 2010.

BioNanomatrix is applying its nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual ultra-long strands of DNA in a massively parallel format. The benchtop system, currently in alpha evaluation, is designed to allow researchers to scan a human genome in as little as 10 minutes, creating an organizational map of each sample. Researchers at beta sites plan to evaluate the instrument for a wide range of applications, from genome integrity to structural variation mapping. Advanced applications, including epigenetic mapping and sequence analysis, will be added later in development.

"This new funding from NHGRI provides additional support as we ramp up for initiation of beta site testing of our first commercial NanoAnalyzer systems, planned for the second quarter of the new year," said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix. "Our nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs, yielding a great deal of genomic information. We are, in essence, providing an imaging tool for genome analysis linking high-resolution sequence data with clinically important structural data in an easy-to-use and highly accessible way. We believe our technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, and we are very pleased that NHGRI is continuing to support our progress towards commercialization."

These two new supplemental grants bring the total that BioNanomatrix has been awarded under the Phase II NHGRI grant program to more than $2.8 million. These grants are part of a Small Business Innovation Research (SBIR) program, awarded under the NIH BECON II nanotech initiative, an interdisciplinary, multi-institutes consortium. BioNanomatrix is also the co-recipient of an $8.8 million multi-year grant from the U.S. National Institute of Standards and Technology Advanced Technology Program (NIST-ATP) to develop a system capable of sequencing the human genome in eight hours at a cost of less than $100.

About BioNanomatrix

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in biomedical research, genetic diagnostics and personalized medicine. The company's platform technology is designed to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs. This technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, providing fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information. Its current development efforts include a NIST-ATP funded project to sequence the human genome at a cost of $100. The company also receives funding from the National Institutes of Health. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: www.BioNanomatrix.com.

    Contact:
    Barbara Lindheim
    GendeLLindheim BioCom Partners
    212 918-4650

SOURCE BioNanomatrix, Inc.


'/>"/>
SOURCE BioNanomatrix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
2. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
3. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
4. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
5. BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board
6. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
7. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
8. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
9. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
10. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
11. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, Inc. ... "Company"), announced that on January 14, 2017 the Board ... which the Company will terminate certain employees associated with ... Inc.  The Company commenced terminations on January 16, 2017 ... days.  The Company may pay severance benefits in certain ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... LOUISVILLE, Ky. and HOUSTON ... Prenatal Inc. ("NX Prenatal") today announced the formation ... brings together leading clinicians and industry veterans who ... the company as it accelerates development of its ... positioned to provide medical, clinical and strategic guidance ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CESĀ® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):